Grisnilimab setaritox (WT1-RTA), an anti-CD7 antihuman T cell antibody linked to ricin A chain (RTA), exhibits in vitro cytotoxicity against CEM (T-lymphoblastic leukemia) cells with an ID 50 of 53 pM. The 30-kDa RTA component disrupts the function of 60S ribosomal subunits. Additionally, Grisnilimab setaritox has demonstrated efficacy in ameliorating leukemic meningitis in a rhesus monkey model [1].

Grisnilimab setaritox（2.5 μg/mL；24小时）对CEM T细胞白血病细胞系展现了明显的细胞毒效应[1]。

在恒河猴的白血病性脑膜炎模型中，Grisnilimab setaritox（60 μg, 120 μg；鞘内注射或静脉注射；单剂量）显示出抑制T-ALL脑膜白血病的效果 [1]。同样地，在恒河猴模型中，Grisnilimab setaritox（60 μg；静脉注射；每周1次，持续6周或每日1次，持续7天）能诱导CSF粒细胞增多症和产生抗免疫毒素抗体 [1]。